Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083122 · ClinicalTrials.gov registry record · Phase 2
Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
A Phase 2 study of Recurrent Ovarian Epithelial Cancer and Stage IV Ovarian Epithelial Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT00083122: Completed Phase 2 study of Recurrent Ovarian Epithelial Cancer and Stage IV Ovarian Epithelial Cancer, sponsored by National Cancer Institute (NCI).
NCT00083122 is a Phase 2 study of Recurrent Ovarian Epithelial Cancer and Stage IV Ovarian Epithelial Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 45 participants, roughly in line with the 46-participant average among 14 other Recurrent Ovarian Epithelial Cancer trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00083122, a Phase 2 study of Recurrent Ovarian Epithelial Cancer and Stage IV Ovarian Epithelial Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well giving cisplatin together with flavopiridol works in treating patients with advanced ovarian epithelial cancer or primary peritoneal cancer. Drugs used in chemotherapy, such as cisplatin and flavopiridol, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
Primary Outcome
A Complete Response (CR) is defined as the disappearance of all target lesions and normalization of tumor biomarkers. A Partial Response (PR) is defined as at least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD. A confirmed tumor response is defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4-6 weeks apart.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG alvocidib
- DRUG cisplatin/flavopiridol
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2004-04 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
What the finished NCT00083122 record still lists
NCT00083122 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, roughly in line with the 46-participant average among 14 other Recurrent Ovarian Epithelial Cancer trials with a reported enrollment target.
The record links to 10 conditions, with Recurrent Ovarian Epithelial Cancer appearing as the primary indexed condition, and to 3 interventions - of which cisplatin is the first listed.
NCT00083122 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00083122 about?
NCT00083122 is a clinical study titled "Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer". This phase II trial is studying how well giving cisplatin together with flavopiridol works in treating patients with advanced ovarian epithelial cancer or primary peritoneal cancer. Drugs used in chemotherapy, such as cisplatin and flavopiridol, work in different ways to stop tumor cells from dividi...
What is the current status of trial NCT00083122?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2004-04. Estimated completion is 2012-05.
What conditions does trial NCT00083122 study?
This clinical trial studies the following conditions: Recurrent Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Primary Peritoneal Cavity Cancer.
What interventions are being tested in trial NCT00083122?
The interventions under investigation include: cisplatin (DRUG), alvocidib (DRUG), cisplatin/flavopiridol (DRUG).
Who is sponsoring clinical trial NCT00083122?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00083122 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Ovarian Epithelial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00083122's enrollment target sits among peer trials
45 8th of 14 higher than 7 of 14 other Recurrent Ovarian Epithelial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Ovarian Epithelial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
COMPLETED · Phase 2
-
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
COMPLETED · Phase 2
-
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
COMPLETED · Phase 2
-
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
COMPLETED · Phase 2
-
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia